Table 1 Estimates of survival following recurrence of glioblastoma
| Â | N | Tx | mPFS | mOS |
|---|---|---|---|---|
Series involving resection ± additional adjuvant Tx at recurrence | ||||
 Quick [26] | 29 | GRT ± RT, CT | NA | 66.5 |
11 | SRT ± RT, CT | NA | 37.4 | |
 DeBonis [11] | 17 | Sx | NA | 26 (13–39) |
19 | No Tx | NA | 22 (13–30) | |
24 | CT | NA | 35 (22–43) | |
16 | Sx + CT ± RT | NA | 61 (43–78) | |
 Clarke [24] | 758 | CT (P II) | 8.3 (8.0–9.6) | 31.4 (25.3–35.9) |
 Park [27] | 34 | Sx | NA | 4–46.8 varies by NRGS |
 McGirt [20] | 294 | Sx (GTR) | NA | 51 |
 Mandl [14] | 9 | Sx (≥1) | NA | 13 |
11 | Sx + SRS/CT | NA | 34 | |
12 | SRS/CT | NA | 28 | |
 Hau [10] | 90 | Sx, RT, CT | 13 (10–13) | 33 (26–39) |
78 | No Tx | 15 % at 12 mos | 9 (4–15) | |
 Pinsker [13] | 38 |  | NA | 18–21 |
 Guyotat [20] | 18 | Sx | NA | 22.6 |
36 | No Sx | NA | 8.6 | |
 Barker [21] | 43 | Sx (≥1) | NA | 42 (37–50) |
130 | No Sx | NA | 23 (20–29) | |
 Landy [11] | 12 | Sx ± RT, CT | NA | 8 |
 Harsh [17] | 39 | Sx | 10 with KPS >70 | 36 |
 Ammirati [18] | 35 | Sx ± RT, CT | NA | 29 |
Series using adjuvant bevacizumab at recurrence | ||||
 Friedman [31] | 85 | Bev | 18.5 (12.6–25.2) | 40 (35.6–46.5) |
 Kresyl [32] | 48 | Bev | 16 (12–26) | 31 (21–54) |
Series using CT (not bevacizumab) at recurrence | ||||
 Lamborn [33] | 437 | CT (P II) | 8 (8–9) | 30 (27–33) |
 Wong [4] | 225 | CT (P II) | 9 (8–10) | 25 (21–28) |